GET DAILY SIGNALS22nd Century Group (XXII) Prepares for Q3 2026 Earnings with Preliminary Signs of Progress
Key Takeaways
- 22nd Century Group is scheduled to report its third quarter 2026 results on November 16, 2026, after releasing preliminary figures in late October.
- Preliminary results point to net revenue of about $4.8 million, up 66% from $2.9 million in the second quarter of 2026.
- Gross profit turned positive at roughly $0.4 million, compared with a $0.3 million gross loss in the prior quarter.
- The company still expects a net loss of approximately $2.6 million, narrower than the $3.3 million loss reported in the second quarter.
- Cash and equivalents stood at $3.9 million at quarter end, with no warrants remaining outstanding.
- For more context, explore 22nd Century Group's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover Trending AI Robots to see AI-driven trading strategies currently drawing attention in the market.
The Broader Context Behind These Earnings
XXII operates as a small-cap tobacco company and remains the sole producer of low-nicotine cigarettes globally. Its VLN® lineup delivers about 95% less nicotine than standard products, placing it squarely in the tobacco harm-reduction space. After shedding unprofitable high-volume lines in 2025, the firm closed the year debt-free and has focused on rebuilding a branded, higher-margin portfolio. The Q3 2026 update matters because it provides the first solid look at whether this shift is taking hold, and early numbers hint at revenue gains plus a return to positive gross profit. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Are Expected to Show
With preliminary results already out on October 22, 2026, investors have a clear baseline. Management anticipates net revenue near $4.8 million for the quarter, reflecting a 66% sequential rise from $2.9 million in Q2. Gross profit should come in around $0.4 million, moving positive after a $0.3 million loss previously. Operating expenses are pegged at $3.0 million, leading to a net loss of roughly $2.6 million versus the prior $3.3 million shortfall. The November 16 release will include full GAAP figures, final earnings per share, and any revised guidance. Adjusted EBITDA is preliminarily forecast at a $2.2 million loss, improved from $3.5 million in the second quarter. From what I see, these trends point to gradual stabilization.
Market Sentiment Heading Into the Report
Investor tone appears measured yet focused. XXII carries a modest share count of roughly 3.4 million common shares as of late October, which can magnify moves on news. The stock saw notable swings in 2026 amid actions like reverse splits. Preliminary data showing the 66% revenue increase and positive gross profit were viewed as positive indicators that the low-nicotine approach is starting to translate into better results. At the same time, ongoing losses and a limited cash position mean investors remain alert to liquidity and execution challenges ahead of the formal update.
Key Items to Watch Going Forward
Distribution stands out as the primary focus after the report. Management continues to broaden reach for VLN® and Partner VLN® brands, so same-store sales trends will signal real consumer uptake. Updates on retail locations, repeat buying patterns, or fresh partnerships will carry more weight than the top-line figure alone. Margin trends also deserve attention—the move to positive gross profit is notable, yet sustainability as production scales remains to be seen. Operating cost control and the pace of loss reduction will likewise draw scrutiny. Cash and liquidity stay central, with $3.9 million on hand and no long-term debt providing some runway that hinges on revenue growth and spending discipline. Regulatory moves from the FDA on reduced-nicotine tobacco could further influence the picture, given XXII’s unique position in this category.
Exploring AI Tools in My Research Process
When analyzing names like this, I often rely on Tickeron’s AI Screener to quickly surface comparable small-cap opportunities and technical signals. It lets me apply filters for industry, volatility, and performance in a fraction of the time it would take manually, helping confirm whether the trends I’m seeing in XXII align with broader sector moves.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XXII in -28.32% downward trend, declining for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XXII declined for three days, in 428 of 441 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for XXII entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for XXII just turned positive on October 06, 2026. Looking at past instances where XXII's MACD turned positive, the stock continued to rise in 24 of 35 cases over the following month. The odds of a continued upward trend are 69%.
XXII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.003) is normal, around the industry mean (-7.598). P/E Ratio (0.000) is within average values for comparable stocks, (13.094). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.595). Dividend Yield (0.000) settles around the average of (0.059) among similar stocks. XXII's P/S Ratio (0.166) is slightly lower than the industry average of (2.780).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. XXII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XXII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 69, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a plant biotechnology company
Industry Tobacco
Advertisement